Stemline Therapeutics, a division of the Menarini Group, is a biopharmaceutical company dedicated to developing and commercializing innovative cancer therapies. Their focus is on first-in-class treatments, exemplified by FDA-approved ELZONRIS for BPDCN and ORSERDU for ER-positive, HER2-negative, ESR1-mutated advanced breast cancer. Stemline continues to research ELZONRIS in other hematologic malignancies and explores ORSERDU's potential in breast cancer treatment, solidifying its position as a leader in oncology therapeutics. Headquartered in New York City, the company aims to improve the lives of cancer patients through targeted therapies.